AI Analysis | Feedback

Allogene Therapeutics is developing the 'off-the-shelf' versions of the highly personalized CAR T-cell cancer therapies offered by companies like Gilead (Kite Pharma) or Novartis.

Imagine companies like Gilead (Kite Pharma) or Bristol Myers Squibb making custom-tailored suits for cancer treatment; Allogene is trying to create the high-quality, ready-to-wear equivalent.

AI Analysis | Feedback

• UCART19: An allogeneic CAR T cell product candidate for relapsed/refractory CD19 positive B-cell acute lymphoblastic leukemia (ALL).
• ALLO-501: An anti-CD19 allogeneic CAR T cell product candidate in development for relapsed/refractory non-Hodgkin lymphoma.
• ALLO-501A: An allogeneic CAR T cell product candidate in development for relapsed/refractory large B-cell lymphoma or transformed follicular lymphoma.
• ALLO-715: An allogeneic CAR T cell product candidate in development for treating relapsed/refractory multiple myeloma.
• ALLO-605: An allogeneic CAR T cell product candidate in development for the treatment of multiple myeloma.
• ALLO-647: An anti-CD52 monoclonal antibody in development, often used as a lymphodepleting agent in CAR T therapies.
• CD70-targeted CAR T cell therapy: An allogeneic CAR T cell product candidate targeting CD70 for the treatment of renal cell cancer.
• ALLO-819: An allogeneic CAR T cell product candidate in development for the treatment of acute myeloid leukemia.
• DLL3-targeted CAR T cell therapy: An allogeneic CAR T cell product candidate targeting DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors.

AI Analysis | Feedback

Allogene Therapeutics (ALLO) is a clinical-stage immuno-oncology company focused on developing allogeneic T cell therapies for cancer. As a clinical-stage company, it does not currently sell finished drug products directly to individuals (patients) or healthcare providers. Instead, its primary interactions are through collaborations, licensing agreements, and partnerships with other pharmaceutical companies and research institutions for the development and potential future commercialization of its therapies.

Based on the provided information, Allogene Therapeutics' major partners and collaborators, who can be considered its "customers" or strategic partners in its current business model, include:

• Pfizer Inc. (Symbol: PFE)
• Servier
• Cellectis S.A. (Symbol: CLLS)
• Notch Therapeutics Inc.
• SpringWorks Therapeutics, Inc. (Symbol: SWTX)

AI Analysis | Feedback

AI Analysis | Feedback

David Chang, M.D., Ph.D. President, Chief Executive Officer and Co-Founder

David Chang is a co-founder of Allogene Therapeutics and has served as President and CEO since June 2018. Prior to Allogene, he was the Executive Vice President of Research & Development and Chief Medical Officer at Kite Pharma, Inc., where he was instrumental in developing Yescarta, the first CAR T therapy approved for non-Hodgkin lymphoma. Kite Pharma was acquired by Gilead Sciences in 2017. He also held senior leadership roles at Amgen from 2002 to 2014, including Vice President of Global Development and Head of Hematology-Oncology. Dr. Chang serves as Board Chair of IconOVir Bio Inc. and is a venture partner at Vida Ventures LLC and Two River.

Geoffrey Parker Executive Vice President, Chief Financial Officer

Geoffrey Parker joined Allogene Therapeutics as Executive Vice President, Chief Financial Officer in October 2023. He is a seasoned biotech and banking executive with nearly 40 years of experience. Before joining Allogene, Mr. Parker served as Chief Operating Officer, Chief Financial Officer, and Executive Vice President of Tricida, Inc. Prior to that, he was the Chief Financial Officer of Anacor Pharmaceuticals, which was acquired by Pfizer in 2016 for approximately $5.2 billion. He also served as a Managing Director at Goldman Sachs, where he led the West Coast Healthcare Investment Banking group for approximately 20 years, completing numerous financing and M&A transactions. Mr. Parker currently serves on the board of directors of Perrigo Company plc and previously served on the board of Better Therapeutics.

Arie Belldegrun, M.D. Executive Chairman and Co-Founder

Arie Belldegrun is a co-founder and Executive Chairman of Allogene Therapeutics. He is a visionary entrepreneur who founded Kite Pharma, a leader in CAR T therapy, and served as its Chairman, President, and CEO until its acquisition by Gilead Sciences in October 2017. Dr. Belldegrun also founded and advanced other successful biopharmaceutical companies, including Cougar Biotechnology, which was acquired by Johnson & Johnson in 2009, and Agensys, acquired by Astellas Pharma in 2007. He currently serves as Chairman of Two River Group, UroGen Pharma, Kronos Bio, and as Co-Chairman of Breakthrough Properties. He is also a co-founder and Senior Managing Director of Vida Ventures.

Zachary J. Roberts, M.D., Ph.D. Executive Vice President, Research & Development, Chief Medical Officer

Zachary J. Roberts is the Executive Vice President, Research & Development, and Chief Medical Officer of Allogene Therapeutics. He is a trained immunologist and board-certified oncologist with extensive experience in clinical oncology and cell therapies. Before joining Allogene, Dr. Roberts was Chief Medical Officer of Instil Bio, where he led clinical and pre-clinical programs. Prior to that, he held various roles at Kite Pharma, where he played a key role in the development and execution of trials for Yescarta. He also previously worked at Amgen as a Medical Director in Hematology/Oncology.

Christine Cassiano Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer

Christine Cassiano is the Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer and one of the founding members of Allogene Therapeutics. She is a communications executive with broad experience in investor relations, corporate communications, media relations, brand strategy, and public affairs. Prior to Allogene, Christine served as Senior Vice President of Corporate Communications and Investor Relations for Kite Pharma until its acquisition by Gilead Sciences. Her career also includes leadership positions at W2O Group and Hill + Knowlton Strategies. She co-founded ARC2 Communications & Media, a boutique agency specializing in healthcare. Christine also serves as a Senior Strategic Advisor to Urogen Pharma and Vida Ventures.

AI Analysis | Feedback

The key risks to Allogene Therapeutics (ALLO) are primarily centered around intellectual property litigation, clinical trial outcomes and regulatory approval, and intense competition within the CAR T-cell therapy market.

1. Intellectual Property Litigation: Allogene Therapeutics faces a significant and material risk due to an ongoing patent infringement lawsuit against its key gene-editing technology licensor, Cellectis S.A.. Allogene's core pipeline, including crucial product candidates like cema-cel and ALLO-316, relies heavily on Cellectis's TALEN-based gene-editing technology. While Allogene is not a direct defendant in the initial complaint, there is a risk that direct claims could be asserted against them as a commercial user of the disputed technology. An adverse ruling in this lawsuit could severely limit Allogene's ability to manufacture or commercialize its allogeneic therapies, potentially leading to injunctions, requiring expensive licensing, or even halting the development of key assets.
2. Clinical Trial Failures and Regulatory Hurdles: As a clinical-stage biotechnology company developing novel allogeneic CAR T-cell therapies, Allogene faces inherent and substantial risks related to the success, safety, and regulatory approval of its product candidates. The company has experienced clinical setbacks, including delays in its pivotal ALPHA3 trial due to various operational challenges. Furthermore, safety concerns have emerged, such as the discontinuation of the ALLO-647 component from the ALPHA3 trial following a Grade 5 serious adverse event. Previous trials for ALLO-316 and ALLO-715 have also reported patient deaths. A past FDA clinical hold on all of Allogene's trials due to a chromosomal abnormality observed in a patient treated with ALLO-501a further underscores the unpredictable nature and safety challenges associated with these advanced therapies. The efficacy of standard lymphodepletion regimens for current trials is also a concern after the discontinuation of ALLO-647, which could impact trial outcomes and regulatory timelines.
3. Intense Competition and Market Acceptance of Allogeneic CAR T-Cell Therapies: The CAR T-cell therapy landscape is highly competitive, with numerous established autologous therapies and emerging novel approaches, including in vivo CAR T. Allogene's allogeneic (off-the-shelf) approach, while offering potential logistical advantages, has yet to receive regulatory approval for any product. This places Allogene in a challenging position, as it must compete with already approved autologous treatments that have longer-term efficacy data and familiarity among oncologists, as well as other companies developing similar allogeneic platforms that could potentially advance more quickly. The unproven commercial track record and complex regulatory pathways for novel technologies further contribute to the risk of gaining significant market share.

AI Analysis | Feedback

null

AI Analysis | Feedback

Allogene Therapeutics (ALLO) develops allogeneic CAR T-cell therapies for various cancers. The addressable markets for their main product candidates are as follows:

Acute Lymphoblastic Leukemia (ALL)

• The CAR T-cell therapy market for Acute Lymphoblastic Leukemia in the 7 Major Markets (7MM, including the US, EU4, and UK, and Japan) was approximately USD 200 million in 2023, with projections for an increase by 2034.
• The U.S. market alone for CAR T-cell therapy in Acute Lymphoblastic Leukemia accounted for approximately USD 150 million in 2023.

Non-Hodgkin Lymphoma (NHL) / Large B-Cell Lymphoma (LBCL)

• The non-Hodgkin lymphoma segment is a significant portion of the overall CAR T-cell therapy market, accounting for 65.46% in 2026.
• The CAR T-Cell Therapy for Non-Hodgkin's lymphoma treatment market size in the United States was approximately USD 1,200 million in 2023 and is expected to increase by 2034.
• The global relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) market is estimated to be valued at USD 1,610.0 million in 2025 and is expected to reach USD 2,161.8 million by 2032.
• The Diffuse Large B-cell Lymphoma market size in the 7MM (US, EU4, UK, and Japan) is projected to grow from USD 5,286 million in 2025 to USD 16,562 million in 2034.

Multiple Myeloma

• The relapsed/refractory multiple myeloma (RRMM) market in the 7MM (US, EU4, UK, and Japan) reached a value of USD 22.0 billion in 2024, with projections to reach USD 37.3 billion by 2035.
• The global relapsed and refractory multiple myeloma treatment market was valued at US$ 23.0 billion in 2025 and is expected to reach US$ 31.5 billion by 2032.
• The global CAR T-cell therapy for multiple myeloma market is expected to grow at a strong 27.0% CAGR from 2023 to 2031.

Acute Myeloid Leukemia (AML)

• The global acute myeloid leukemia treatment market size was valued at USD 2.82 billion in 2025 and is expected to reach USD 7.65 billion by 2035.
• In 2026, the global acute myeloid leukemia treatment market is assessed at USD 4.28 billion, projected to reach approximately USD 10.64 billion by 2035.
• North America is expected to hold a significant share of the acute myeloid leukemia market, accounting for approximately 38.2% in 2025.

Small Cell Lung Cancer (SCLC)

• The global small cell lung cancer therapeutics market size is valued at USD 7.25 billion in 2025 and is predicted to increase to approximately USD 22.86 billion by 2035.
• The 7MM (US, Germany, UK, France, Italy, Spain, and Japan) small-cell lung cancer market reached USD 8.9 billion in 2024 and is projected to reach USD 23.0 billion by 2035.
• North America held the major market share for more than 40% of the global small cell lung cancer therapeutics revenue, with a market size of USD 2609.80 million in 2025.

Renal Cell Cancer (RCC)

• The global renal cell carcinoma market size reached a value of USD 4.6 billion in 2023 and is expected to reach USD 7.3 billion by 2034.
• The global advance renal cell carcinoma therapeutics market is estimated to be valued at USD 7.4 billion in 2025 and is projected to reach USD 12.5 billion by 2035.
• North America dominates the renal cell carcinoma market.

AI Analysis | Feedback

1. Advancement and Potential Commercialization of Cema-cel (ALLO-501A) in Large B-Cell Lymphoma (LBCL): Allogene's most advanced product candidate, cema-cel, is currently in the pivotal Phase 2 ALPHA3 trial for first-line consolidation in large B-cell lymphoma. Management views 2026 as a critical year, with pivotal data from ALPHA3 expected in April. Successful clinical outcomes and eventual regulatory approval of cema-cel could unlock a substantial market opportunity, estimated by management to be around $5 billion across the U.S. and Europe, with potential peak sales exceeding $2 billion.
2. Progression and Potential Commercialization of ALLO-329 in Autoimmune Diseases: Allogene is strategically expanding its allogeneic cell therapy platform into autoimmune diseases with ALLO-329, a dual CD19/CD70 CAR T product candidate. The company expects to report proof-of-concept data for ALLO-329 in June 2026. Entering the autoimmune disease market represents a significant growth opportunity, as analysts have estimated the revenue potential for CAR T therapy in autoimmune diseases in the U.S. alone to be between $150 billion and $263 billion.
3. Advancement of Other Oncology Pipeline Candidates, including ALLO-715 and ALLO-316: Beyond its lead programs, the continued clinical progression of other allogeneic CAR T candidates holds future revenue potential. ALLO-715, an anti-BCMA CAR T for multiple myeloma, has shown promising Phase 1 results. Additionally, ALLO-316, targeting CD70 for renal cell carcinoma, has demonstrated clinically significant response rates in a metastatic solid tumor setting and the company is exploring partnering opportunities to advance this asset. Successful development and potential commercialization or out-licensing of these assets would contribute to long-term revenue growth.
4. Strategic Collaborations and Licensing Agreements: Allogene has established collaborations with pharmaceutical companies such as Pfizer and Servier, and a licensing agreement with Cellectis for its gene-editing technology. While not immediate product sales, the successful advancement of partnered assets like UCART19 (an anti-CD19 candidate developed with Servier and Pfizer for acute lymphoblastic leukemia) could lead to milestone payments and future royalties. The overall success of these collaborations and the potential for new partnerships driven by their allogeneic platform could also be a source of future revenue.

AI Analysis | Feedback

Share Issuance

• In May 2024, Allogene Therapeutics announced the pricing of an underwritten offering of 37,931,035 shares of its common stock at $2.90 per share, which was expected to generate gross proceeds of approximately $110 million.
• As of March 2026, the company had raised an additional $20.7 million year to date through its at-the-market (ATM) equity facility.
• The weighted average diluted shares outstanding increased from 143.15 million in 2022 to 194.81 million in 2024, reflecting these issuances.

Inbound Investments

• In February 2026, Allogene received $23.7 million in escrow funds related to a favorable arbitration outcome between Servier and Cellectis.

Outbound Investments

• Allogene expanded its strategic collaboration with Foresight Diagnostics in February 2025, involving an investment of approximately $37.3 million for MRD assay development, milestone payments, and clinical sample testing.
• In January 2022, Allogene entered into an exclusive collaboration and global license agreement with Antion Biosciences, which included an upfront cash payment and a preferred equity investment.